Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 6
2004 5
2005 4
2006 5
2007 6
2008 12
2009 12
2010 4
2011 10
2012 9
2013 18
2014 11
2015 18
2016 18
2017 20
2018 9
2019 20
2020 25
2021 29
2022 32
2023 29
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

287 results

Results by year

Filters applied: . Clear all
Page 1
Corrigendum to "Fibrolamellar carcinomas-growth arrested by paracrine signals complexed with synthesized 3-O sulfated heparan sulfate oligosaccharides" [Matrix Biology 121(August 2023), 194-216].
Zhang W, Xu Y, Wang X, Oikawa T, Su G, Wauthier E, Wu G, Sethupathy P, He Z, Liu J, Reid LM. Zhang W, et al. Among authors: wang x. Matrix Biol. 2024 Apr 1:S0945-053X(24)00041-6. doi: 10.1016/j.matbio.2024.03.004. Online ahead of print. Matrix Biol. 2024. PMID: 38565465 No abstract available.
Molecular features of gastroenteropancreatic neuroendocrine carcinoma: A comparative analysis with lung neuroendocrine carcinoma and digestive adenocarcinomas.
Zhang J, Chen H, Zhang J, Wang S, Guan Y, Gu W, Li J, Zhang X, Li J, Wang X, Lu Z, Zhou J, Peng Z, Sun Y, Shao Y, Shen L, Zhuo M, Lu M. Zhang J, et al. Among authors: wang x. Chin J Cancer Res. 2024 Feb 29;36(1):90-102. doi: 10.21147/j.issn.1000-9604.2024.01.09. Chin J Cancer Res. 2024. PMID: 38455367 Free PMC article.
First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial.
Ren S, Wang X, Han BH, Pan Y, Zhao J, Cheng Y, Hu S, Liu T, Li Y, Cheng Y, Feng J, Yi S, Gu S, Gao S, Luo Y, Liu Y, Liu C, Duan H, Wang S, Yang X, Fan J, Zhou C. Ren S, et al. Among authors: wang x. J Immunother Cancer. 2024 Feb 21;12(2):e007227. doi: 10.1136/jitc-2023-007227. J Immunother Cancer. 2024. PMID: 38388167 Free PMC article. Clinical Trial.
Helicobacter pylori and immunotherapy for gastrointestinal cancer.
Jia K, Chen Y, Xie Y, Wang X, Hu Y, Sun Y, Cao Y, Zhang L, Wang Y, Wang Z, Lu Z, Li J, Zhang X, Shen L. Jia K, et al. Among authors: wang x. Innovation (Camb). 2024 Jan 8;5(2):100561. doi: 10.1016/j.xinn.2023.100561. eCollection 2024 Mar 4. Innovation (Camb). 2024. PMID: 38379784 Free PMC article.
287 results